It is unclear whether testing for novel risk factors, such as a cardiovascular genetic risk score (cGRS), improves clinical decision making or health outcomes when used for targeting statin initiation in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Our objective was to estimate the cost-effectiveness of cGRS testing to inform clinical decision making about statin initiation in individuals with low-to-intermediate (2.5%-7.5%) 10-year predicted risk of ASCVD.
O ver 1.2 million Americans experience a first atherosclerotic cardiovascular disease (ASCVD) event (myocardial infarction [MI] , coronary heart disease death, or stroke) every year. 1 Statins, a group of highly efficacious lipid-lowering agents, significantly reduce the risk of MI, stroke, and coronary heart disease (CHD) death and are recommended as preventive therapy in nondiabetic, ASCVD-free individuals who have a 10-year predicted ASCVD risk (calculated using the pooled cohort equations) ≥7.5%. 2, 3 However, the pooled cohort equations alone may not be optimal for guiding statin treatment decisions in individuals close to the 7.5% treatment threshold, given the wide variance inherent in individual-level risk estimates and variation in patient preferences for daily medication use. [4] [5] [6] [7] Furthermore, the 7.5% threshold is based on expert opinion, rather than evidence from cost-effectiveness analyses. 2 Apart from the 7.5% threshold, the 2013 American College of Cardiology/American Heart Association guidelines on ASCVD risk reduction suggest testing for nontraditional risk factors-such as coronary artery calcium (CAC), ankle-brachial index, and high-sensitivity C-reactive protein-to provide information about other aspects of risk not covered by traditional risk factors, such as atherosclerotic burden or vessel reactivity, and to assist clinicians and patients during shared decision making about statin initiation. 3 Although there is no consensus on which nontraditional risk factors are most clinically useful or how to interpret risk factor test results in the context of existing ASCVD-predicted risk estimates, decision modeling can be used to help determine clinical utility of testing for new nontraditional risk factors such as CAC. 8, 9 Cardiovascular genetic risk testing provides the opportunity to more precisely identify individuals at high risk for developing ASCVD for whom preventive therapy, such as statins, can be directed. [10] [11] [12] [13] [14] [15] [16] An individual's cardiovascular genetic risk score (cGRS) may reflect genetic susceptibility to accelerated atherosclerosis potentially related to errors in cholesterol metabolism, thrombosis, and other endothelium-related factors. 17 In 2015, Mega et al 18 demonstrated a significant, independent association between a 27-single-nucleotide polymorphism (SNP) cGRS and cardiovascular disease outcomes after accounting for traditional ASCVD risk factors. However, it is unclear whether its impact on predicted risk produces important differences in clinical decision making regarding statin initiation or ultimately improves cardiovascular outcomes. [10] [11] [12] [13] [14] [15] [16] In the absence of large, generalizable randomized controlled trials comparing clinical management with and without additional testing for novel risk factors, clinical decision analysis and cost-effectiveness or cost-utility modeling can be used to explicitly compare alternative clinical options regarding their relative downstream risks, benefits, and costs. 8, 19, 20 In this study, we used modeling to evaluate the clinical utility and cost-effectiveness of cGRS testing for targeting statin therapy in the primary prevention of ASCVD.
METHODS
The cost-effectiveness model described below will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, the structure, inputs, and assumptions of the model have been described in sufficient detail both here and in previous publications for interested analysts to reproduce the model. Because of the nature of this study, an institutional review board approval was waived.
Overview and Model Structure
The UNC-RTI CHD Prevention Model is a state-transition Markov model that can be used to compare incidence of ASCVD events, mortality, quality of life, and costs with and without a prevention intervention, such as aspirin or statin therapy, for specific clinical scenarios over a lifetime horizon. A detailed description of the model and validation has been published elsewhere. 8, [21] [22] [23] [24] Briefly, a specific clinical scenario is defined by age, sex, and ASCVD risk factors, including systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking status, and antihypertensive medication use (Appendix A in the Data Supplement). A cohort of 10 000 individuals with defined characteristics begins in the healthy state and then transitions every 12 months as described in Figure 1A . Myopathy, angina, MI, and stroke are modeled as separate health states. Costs, quality of life, and mortality rates differ in each state. Tables 2 through 4) . 25 We updated the UNC-RTI CHD Prevention Model to include cGRS testing strategies. Specifically, we used the model to compare 4 different interventions:
1. Two strategies where statin prescribing does not depend on results of cGRS testing (treat none and treat all) and 2. Two strategies for which a cGRS test is ordered and statins are prescribed only if the cGRS is above a threshold (treat if cGRS is intermediate or high and treat if cGRS is high; Figure 1B ). Statin prescribing was assumed to be differential for 10 years, but cumulative costs and quality-adjusted life-years (QALYs) were simulated across a full lifetime horizon to fully account for the consequences of a life saved or MI prevented by statins during those first 10 years of differential treatment. We assumed that after 10 years, most individuals have increased enough in risk that the decision about initiating statin treatment would no longer depend on the baseline risk or results of genetic testing. Thus, after 10 years, all individuals are assumed to be on statins for primary prevention, if not already on statins for secondary prevention. We have previously used these methods to model cost-effectiveness of CAC scanning. 8, [21] [22] [23] [24] Our primary outcomes were ASCVD events, life-years, QALYs, costs, and the incremental cost-effectiveness ratio measured in cost per QALY gained. Life-years, QALYs, and costs were discounted at 3% per annum. We identified preferred strategies under the assumption that society is willing to pay ≤$50 000 per QALY gained. Our secondary outcome measures were (1) net benefit (in QALYs) defined as the balance of benefits and harms for a strategy over the lifetime horizon at a willingness-to-pay (WTP) threshold of <$50 000 per QALY and (2) gain in QALYs.
cGRS Testing Parameters
Costs for genetic risk testing vary based on the number of SNPs genotyped and the laboratory at which the genotyping is performed. 26 We assumed, based on expert opinion, a base case cost of $100 but varied the cost between $1 and $1000 in sensitivity analyses. 27 We also added the cost of one physician visit to discuss cGRS test results with patients.
For each of our base case clinical scenarios, we accounted for the expected distribution of cGRS using a prediction model derived from Add Health data to estimate the proportion of scores falling into categories of low risk, intermediate risk, and high risk, using methods described previously. 28, 29 The expected distribution of cGRS was not associated with the other ASCVD risk factors. We then estimated posttest risk for angina, MI, and CHD death in these categories using cGRS-specific relative risks and previously described methods (Appendix F in the Data Supplement; Tables 1 through 4) . 18, 29, 30 We assumed that the risk of stroke did not vary with cGRS.
Statin Treatment Parameters
In our base case scenario, we assumed that statins can be obtained at a cost of $4 per month (2017 Walmart Retail Prescription Program Drug List) and that taking a statin pill every day is associated with a small reduction in quality of life (disutility of 0.001). The disutility of daily statin use represents any reason that a patient might prefer not to take a pill daily, such as inconvenience or reduction in self-conception of health but does not include adverse effects. 7 We also assumed that statin therapy triggers one additional physician visit and lipid panel per year. Furthermore, we assumed that statins are associated with relative reductions in risk of MI (26%), angina (26%), stroke (15%), and CHD death (20%), as well as increased risk of myopathy (absolute rate of 0.001 cases per year). 31 Associated cost, mortality, and disutility are applied for the current 1-year cycle, and it is assumed that statins are discontinued. We also assumed immediate discontinuation of statins in 31% of individuals to simulate the effect of nonadherence to treatment. 32 There is evidence that statin initiation is associated with a small but statistically significant increase in hemoglobin A1C (HbA1C) and new diagnoses of diabetes mellitus with highdose therapy. 33 The short-term cardiovascular risks are implicitly accounted for in the statin efficacy estimates from clinical trials. 31 The long-term cardiovascular risks associated with this small increase in HbA1C are not well understood. 33 Thus, in this model, we assumed no long-term risk of diabetes mellitus that may be associated with the slight increase in HbA1C because of statin initiation. 
Event and Health State Costs
Total costs were assessed from the US healthcare system perspective, adjusted to the year 2016 using consumer price indices (medical care component). Acute care costs within the UNC-RTI CHD Prevention Model were estimated using data on hospital charges from the Healthcare Utilization Project database and converted to costs using hospital charge-tocost ratios (Table 1) . [21] [22] [23] [24] 34 In addition to the acute care costs, we assumed that each patient who survived an acute event would also incur one half of the estimated ongoing annual costs of care for the first year. Costs for subsequent years were based on ongoing costs of care that were drawn from the medical literature. [35] [36] [37] [38] [39] Additional references for these model assumptions and a complete Consolidated Health Economic Evaluation Reporting Standards checklist are provided in Appendixes C and E in the Data Supplement.
ASCVD Risk Factor Profiles
We created 5 ASCVD risk factor profiles to illustrate important findings from our base case and scenario analyses: (1) a 57-year-old man at 7.5% risk (profile 1); (2) a 65-year-old woman at 7.5% risk (profile 2); (3) a 45-year-old woman at 2.5% risk (profile 3); (4) a 45-year-old woman at 5% risk (profile 4); and (5) a 45-year-old woman at 7.5% risk (profile 5; Appendix A in the Data Supplement). We selected these profiles to illustrate the effect of varying sex (profile 1 versus 2), age (profile 2 versus 5), and baseline ASCVD risk on outcomes (profile 3 versus 4 versus 5).
For interested readers, we have also included the base case results for 21 additional ASCVD risk profiles ranging from 0.25% to 7.5% 10-year ASCVD risk in the Data Supplement (Appendix G in the Data Supplement; Tables 1 and 2 ).
Sensitivity Analyses
We varied incidence of myopathy, disutility for myopathy, and statin effect modification in a 1-way deterministic sensitivity analysis (Table 1) . There is some evidence to suggest that individuals with high cGRS have a larger relative risk reduction for CHD events when taking statins compared with individuals at low and intermediate cGRS. 40 To investigate the influence of statin effect modification, we increased the relative risk reduction associated with statin treatment for individuals with high cGRS while proportionally reducing the relative risk reduction associated with statin treatment for individuals with low and intermediate cGRS.
We chose to increase the relative risk reduction for individuals with high cGRS by 3-fold to illustrate the sensitivity of results to statin effect modification rather than test the exact relative risk reduction values published by Natarajan et al (calculation described in detail in Appendix B in the Data Supplement).
We performed a 2-way sensitivity analysis of statin disutility and statin cost by varying the cost of statins from $2 per month to $200 per month and the disutility of daily statin use from 0 to 0.10. 7, 41 For context, a disutility of 0.02 is equivalent to 10 weeks of perfect health traded away to avoid 10 years on statins. 7 Hutchins et al found that the majority of individuals (87%) have a statin disutility of 0, but we tested values up to 0.10 to demonstrate the sensitivity of the results to higher levels of statin disutility.
We completed the same 2-way sensitivity analysis for profiles 1 to 5 to demonstrate the importance of specific ASCVD risk factors, in addition to 10-year ASCVD risk, on the preferred strategies for different combinations of statin cost and disutility. For interested readers, we have also shown how the 2-way sensitivity table changes when using a WTP threshold of $50 000 per QALY gained versus $100 000 per QALY (Appendix D in the Data Supplement).
To examine the role of statin cost, statin disutility, and cGRS test characteristics, we show scenario analyses that vary statin cost, statin disutility, cost of cGRS testing, and the strength of the relationship between the 27-SNP cGRS and cardiovascular disease outcomes (Table 2) .
We conducted a probabilistic sensitivity analysis using second-order Monte Carlo simulation (n=1000 trials) to determine the effect of parameter uncertainty on the probability of cost-effectiveness for the scenario analyses (Table 2) . Parameter ranges are reported in Table 1 . We parameterized costs using γ distributions, disutilities using β distributions, and relative risks using lognormal distributions. 42 Finally, we show cost-effectiveness acceptability curves for the 57-year-old man (profile 1) for 2 statin cost/disutility combinations from the 2-way sensitivity analysis (cost=$15 per month, disutility=0.011; cost=$15 per month, disutility=0.013) to illustrate how the probability of cost-effectiveness changes with WTP threshold.
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RESULTS
Base Case Assumptions
Under base case assumptions, treating all patients without any cGRS testing was cost saving and dominated all other test/treat strategies for a cohort of 10 000 57-year-old men at 7.5% ASCVD risk (Table 3 ) over a lifetime horizon. Compared with treating no one, the cohort of 10 000 men experienced 53 fewer MIs, 1 fewer strokes, 139 fewer cases of angina, and 23 fewer CHD deaths but 65 more cases of myopathy. When treating all patients with statins, the total statin costs over a lifetime horizon were $949 per patient and the total costs (including other healthcare costs) were $146 545 per patient. Treating none of the patients had total statin costs of only $229 per patient but total overall costs of $147 003 per patient. Treating all patients without cGRS testing was also cost-saving and dominated all other strategies for a cohort of 10 000 65-year-old women with 7.5% 10-year ASCVD risk (Table 4 ; profile 2). For the 45-year-old women at 2.5%, 5%, and 7.5% 10-year ASCVD risk, the recommendation was to treat all with no cGRS testing, and the gain in QALYs associated with that strategy (compared with treat none) increased with increasing 10-year ASCVD risk (base case scenario; Table 4 ). Furthermore, the gain in QALYs associated with treating all 65-yearold women at 7.5% 10-year ASCVD risk is lower than the gain in QALYs associated with treating all 45-year-old women at 7.5% 10-year ASCVD risk. For profiles 1 to 5, under base case assumptions, the probability of costeffectiveness of treat all with no cGRS testing compared with treat none with no cGRS testing was 100%.
We analyzed 11 additional ASCVD risk profiles representing risk levels between 2.5% and 7.5% (Appendix G in the Data Supplement; Table 1 ) and found that the preferred test/treat strategy under base case assumptions for all profiles was also to treat all patients without cGRS testing. For a set of example low-risk profiles ranging from 0.25% to 1.0% 10-year ASCVD risk, we found that the preferred test/treat strategy varied depending on both risk and specific ASCVD risk profile (Appendix G in the Data Supplement; Table 2 ). For all the profiles at 1.0% risk, the preferred test/treat strategy was to treat all without any cGRS testing; however, at 0.5% 10-year ASCVD risk, the preferred test/treat strategy was different across ASCVD risk profiles. For example, the base case preferred strategy for a 40-yearold woman at 0.5% risk was to treat none without cGRS testing, whereas the base case preferred strategy for a 45-year-old woman at 0.5% risk was to test and treat only if cGRS is high (Appendix G in the Data Supplement; Table 2 , profiles 20-21). At 0.25% 10-year ASCVD risk, the preferred strategy for all example profiles was treat none without any cGRS testing. 
One-Way Sensitivity Analyses: Incidence of Myopathy, Disutility of Myopathy, and Statin Effect Modification
We conducted a 1-way sensitivity analysis of key model parameters using 10 000 57-year-old men at 7.5% ASCVD risk. The base case recommendation to treat all without any cGRS testing did not change with varying the incidence or disutility of myopathy throughout the ranges listed in Table 1 . Furthermore, assuming a statin effect modification did not change the recommendation to treat all without any cGRS testing. ASCVD indicates atherosclerotic cardiovascular disease; CE, cost-effectiveness; cGRS, cardiovascular genetic risk score; QALY, quality-adjusted life-years; and RR, relative risk.
*Strong dominance indicates that the strategy listed is more effective (higher QALYs) and less costly than the next most effective strategy. †Gain in QALYs=difference between preferred strategy and treat none. ‡Probability of CE is taken from the probabilistic sensitivity analysis for each of these scenarios and risk profiles.
Two-Way Sensitivity Analysis: Statin Disutility Versus Statin Cost
The specific combinations of statin disutility and statin cost that lead to cGRS testing as a preferred strategy were uncommon and dependent on the ASCVD risk factors for the specific profile considered (Figure 2 ). For example, for the 57-year-old man at 7.5% risk, only one combination of statin disutility/statin cost combinations led to a cGRS testing strategy being preferred (profile 1; Figure 2A ). None of the statin disutility/statin cost combinations led to a preferred strategy that involved cGRS testing for the 65-yearold woman at 7.5% ASCVD risk (profile 4; Figure 2B ). However, cGRS testing was preferred for several statin disutility/statin cost combinations for the 45-year-old woman with 7.5% 10-year ASCVD risk (profile 3; Figure 2C ).
Scenario Analyses: cGRS Testing Cost, Statin Disutility, Statin Cost, and RR Associated With CHD Outcomes
Varying the cGRS testing cost alone did not change the preferred test/treat strategy for the ASCVD profiles considered (Table 4 ; scenario #1 versus base case). However, when statin disutility was increased, cGRS testing became the preferred strategy for the 45-year-old women at 5% and 7.5% 10-year ASCVD risk if cGRS testing cost was decreased (scenario 4 versus scenario 2) along with an increase in the cost of statins (scenario 3 versus scenario 2). When both statin disutility and statin cost were increased compared with base case assumptions, the cost of cGRS testing did not affect the preferred strategy for any of the profiles shown. Finally, under base case assumptions for statin disutility and statin cost, increasing the strength of the association between the cGRS results and CHD outcomes (to simulate a hypothetical better cGRS test) did not affect the preferred strategy, even when the hypothetical better cGRS test was inexpensive (scenarios 5 and 6 versus base case). In general, treat none is preferred when the cost and disutility of statins are high.
Probabilistic Sensitivity Analysis
For the 57-year-old man at 7.5% risk (profile 1) using base case assumptions (scenario 1), the probability of cost-effectiveness for treat all is 100% when compared with the next best strategy (test and treat if cGRS is intermediate or high), at a WTP threshold of $50 000 per QALY. Figure 3 shows the cost-effectiveness acceptability curves for the 57-year-old man at 7.5% risk (profile 1) for 2 combinations of statin cost and disutility to illustrate the importance of statin disutility on the relationship between WTP threshold and probability of cost-effectiveness. For the first combination of statin cost/disutility ( Figure 3A) , none of the cGRS testing strategies are preferred at any WTP threshold. In Figure 3B , the statin cost is the same, but statin disutility is higher. Here, the preferred strategy is dependent on the WTP threshold. For example, the preferred strategy for WTP thresholds between $0 per QALY gained and around $9000 per QALY gained is test and treat if cGRS is high, compared with WTP thresholds >$9000 per QALY gained, for which the preferred strategy is test and treat if cGRS is intermediate or high. Furthermore, the probability of cost-effectiveness for each test/treat strategy is closer for Figure 3B , indicating that uncertainty in parameter assumptions plays an important role in determining the preferred test/treat strategy at different WTP thresholds. The probability of cost-effectiveness for the preferred strategies varied considerably across profiles and scenarios (Table 4) . In general, when statin disutility and statin cost were set at their base case assumptions (base case, scenarios 1, 5, and 6), the probability of cost-effectiveness for the preferred strategy (assuming a WTP threshold of $50 000 per QALY gained) of treat all was either at or close to 100%. For the scenarios in which a cGRS testing strategy was preferred, the probability of cost-effectiveness for that strategy ranged from 43% to 91%, indicating substantial parameter uncertainty even for this most favorable scenario for cGRS testing.
DISCUSSION
In a set of clinical scenarios of individuals with 10-year predicted ASCVD risk ranging from 2.5% to 7.5%, obtaining a cGRS test to target statin therapy for primary prevention of ASCVD was not a cost-effective strategy at a WTP of $50 000 per QALY gained. Instead, we found that the preferred strategy is to treat all patients with statins under base case assumptions of low-cost statins and low statin disutility. However, cGRS testing can be cost-effective under a small set of assumptions related to statin cost and statin disutility that depend on sex, age, 10-year ASCVD risk, and WTP threshold.
In our example of a 45-year-old woman with 10-year ASCVD risk of 2.5%, the preferred strategy under base case assumptions is to treat all without any testing. Although this 10-year ASCVD risk is much lower than current thresholds for recommended statin therapy, our findings are consistent with the work of Pandya et al 41 that demonstrate that 10-year ASCVD risk thresholds <5% for recommending statin can be cost-effective. We chose to limit our analysis to individuals with 10-year ASCVD risk of ≤7.5% because at higher levels of risk, treat all is the preferred strategy even with wide variation in assumptions about statin disutility and cost.
Furthermore, the sensitivity of our results to statin cost and statin disutility is consistent with previous work on the cost-effectiveness of statin therapy in intermediate-risk patients. 8, 41 A recent study found that the prevalence of statin disutility >0.01 (trading away 5 weeks of perfect health to avoid 10 years on statins) was ≈7.4%, with 87% of individuals being unwilling to trade any length of time to avoid statin therapy. 7 Given that net benefit from statin therapy relies heavily on assumptions about statin disutility, it may be reasonable to ask patients how much the idea of taking a daily preventive medication bothers them during shared decision making regarding statin initiation. In the absence of knowledge about an individual patient's disutility for taking daily preventive medications, we can assume that the conditions under which cGRS testing is the preferred strategy are uncommon during routine clinical practice.
When we examined the 2-way sensitivity analysis (statin disutility versus statin cost) for the 65-year-old woman at 7.5% 10-year ASCVD risk (profile 4), we did not find any combinations of statin disutility and statin cost that led to a cGRS testing strategy being preferred. In contrast, cGRS testing was preferred for the 45-yearold woman at 7.5% 10-year ASCVD risk for many combinations of statin disutility and statin cost. These findings demonstrate the importance of the underlying clinical risk factors that determine 10-year ASCVD risk, especially age. When simulating a lifetime horizon, the treated 45 year old has more years to accumulate benefit from cGRS testing compared with a 65 year old. Conversely, the untreated 45 year old also has more years to avoid disutility of treatment compared with the 65 year old. Thus, it is important to be able to make risk-based and preference-based decisions about cGRS testing (as well as testing for other novel biomarkers). Future work should be done to test the best way to operationalize in clinical practice. 44 Although the 27-SNP cGRS test is an independent predictor of ASCVD outcomes, the strength of the association is small. 18 Other approaches to targeting statin therapy, such as the selective use of imaging (CAC scanning), are substantially better at improving discrimination and reclassification in intermediate-risk patients. 6 However, although CAC scanning improves risk prediction, it has also been shown to be cost-effective only under a limited set of assumptions for statin disutility and cost. 8, 9 In the future, other versions of cGRS tests may need to focus on incorporating gene variants related to the cardiovascular risk pathways that do not overlap with traditional risk factors, such as inflammation and thrombosis. 11 Our work has some limitations. We did not attempt to account for any change in a patients' adherence or motivation to improve lifestyle factors based on receipt of genetic risk information because of limited evidence supporting this assumption. Furthermore, we did not explicitly account for new-onset diabetes mellitus in the model. However, as previously stated, although there is evidence that statin initiation is associated with a small but statistically significant increase in HbA1C and new diagnoses of diabetes mellitus, the cardiovascular benefits outweigh the risks, at least in the short term. 33 And, it is unclear whether there are long-term microvascular implications associated with the small increase in HbA1C or slightly earlier diagnosis of diabetes mellitus. We also did not attempt to account for any patient-level differences in risk for myopathy. Current evidence suggests that there may be some increased risk when used in combination with certain drugs or with certain patients (individuals of Asian origin or with functional variations of the SLCO1B1 gene). 45 . However, we do not explicitly model differences in ethnicity in our model, and the 27-SNP genetic risk score does not include information about the functional status of the SLCO1B1 gene. Thus, we chose not model any subpopulations with increased risk for myopathy. Finally, we chose to show results for only 5 clinical profiles, which limits generalizability of our results. Future work could extend the current analysis to include a full set of clinical profiles that is representative of some population of interest.
Decision modeling and cost-effectiveness analyses are methods used to explicitly compare alternative clinical options regarding their relative downstream risks, benefits, and costs. In March 2017, the National Academy of Science and Medicine published a framework for evaluation of genetic tests that endorsed the use of clinical decision analysis as a way to assess both clinical utility and cost-effectiveness of new genetic tests. 27 The work presented here is an example of the type of analysis that can help identify conditions under which genetic risk testing may (or may not) be a cost-effective approach for tailoring decisions about initiation of preventive therapies for individual patients.
Results from decision analyses can also be used to decide whether to invest in large-scale and expensive clinical trials to definitively assess the clinical utility of cGRS testing or whether to invest in commercialization. For example, the 27-SNP cGRS test used in this analysis is not currently marketed, and commercialization would require investment in the equipment and processes necessary to assure analytic validity. 46, 47 The test developer would need to charge a high enough price for the test to ensure return on investment for research and development. However, depending on the price, our findings demonstrate that the cost of cGRS testing and the strength of association between the cGRS and CHD outcomes play a limited role in determining the overall clinical utility of cGRS testing for guiding statin therapy.
CONCLUSIONS
Our analyses demonstrate that cGRS testing is not a cost-effective approach for targeting statin therapy in the primary prevention of ASCVD in patients with 10-year ASCVD risk of ≥2.5%. Although there are a small set of combinations of parameters under which cGRS testing strategies would be preferred, these are unlikely to be encountered in routine clinical practice.
